Navigation Links
MedImmune Licenses Reverse Genetics Technology to Hungary's Omninvest for Use in Influenza Vaccine Development and Production
Date:10/16/2008

Second Agreement Signed in Third Quarter of 2008 Expands Worldwide

Application of Cutting-Edge Influenza Vaccine Technology

GAITHERSBURG, Md., Oct. 16 /PRNewswire/ -- MedImmune announced today that it has licensed its proprietary reverse genetics intellectual property to Omninvest, a Hungarian research and manufacturing company, to support the development and construction of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only with segments of the virus's genome. This announcement marks the second agreement of this kind that MedImmune signed in the third quarter of 2008.

"Omninvest has demonstrated decades of commitment to providing protection against influenza, and we commend their commitment to donate some of their product to the World Health Organization (WHO) stockpile for distribution among developing nations," said MedImmune's Jonathan Klein-Evans, vice president, intellectual property. "MedImmune is pleased to license our reverse genetics technology to Omninvest as we have done previously to five other influenza vaccine manufacturers."

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates because it allows them to avoid working directly with the infectious, circulating pandemic strains. As the owner or exclusive licensee of key patent estates for use of the rev
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
2. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
3. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
4. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
5. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
6. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
7. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
8. Seneca Valley High School Student Receives Science Award From MedImmune
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. MedImmune Submits Biologics License Application to FDA for Motavizumab
11. MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... N.H. , April 1, 2015 Emerson ... IGNITE: The Business of Better Medicine . The ... business knowledge to develop a thriving and fulfilling practice. ... the Omni La Costa Resort and Spa, the conference ... attendees can expect to accomplish key projects and leave ...
(Date:4/1/2015)... 1, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... pleased to announce that Biohaven Pharmaceutical Holding Company ... entered into an agreement with inVentiv Health for ... with their lead compound (BHV-0223). ... of clinical stage neuroscience compounds targeting the glutamatergic ...
(Date:4/1/2015)... Canada,s Research-Based Pharmaceutical Companies (Rx&D) acknowledges ... on Cost Drivers of Public Drug Plans in ... the rates of change in drug costs have been steadily ... in 2012/13 for a number of select public drug plans. ... of medicines without considering their overall impact on the system ...
(Date:4/1/2015)... 2015 Holomic is introducing the HRDR-400, ... chromatographic and fluorescent rapid tests with one device. ... quantitative readers and is already selling its HRDR-200 chromatographic ... first of its kind offering for manufacturers and end-users ... Dr. Neven Karlovac, CEO of Holomic LLC, commented, "We ...
Breaking Biology Technology:Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 2Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 3Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2
... AMSTERDAM, August 17 SynCo Bio Partners, ... a strategic partnership to produce Versartis, lead drug candidate,VRS-859, ... type 2 diabetes,Under the agreement, SynCo will further develop ... manufacturing process to,increase yields for the forthcoming cGMP production. ...
... , , , ... BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading manufacturer ... today announced that it has entered into a non-exclusive distribution ... STEMCELL Technologies, a member of the StemCell Group of companies, ...
... MD, and Christchurch, NZ June 25, 2009 ... detection solutions, today reported that new independent data to ... the exceptional accuracy of its Ceeker (pronounced "seeker") portable ... similar-looking hoax substances. The data show that in ...
Cached Biology Technology:SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 3Novel handheld device detects anthrax with outstanding accuracy and reliability 2Novel handheld device detects anthrax with outstanding accuracy and reliability 3
(Date:3/12/2015)... BERLIN , March 12, 2015 ... IAM, a standardized identity and access management (IAM) ... reliable implementation schedule. With Beta System,s new IAM ... and best practices gleaned from multiple IAM implementations ... includes the software as well as any necessary ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... In a first-of-its-kind clinical trial, physician-scientists at University Hospitals ... Western Reserve University School of Medicine are studying a ... five-year study is recruiting patients to compare the effectiveness ... large colon polyps. SDNA is a ...
... geneticist Alexander Varshavsky (California Institute of Technology, USA), who was ... 1977, has been awarded the Otto Warburg Medal of the ... is considered to be the highest German award for biochemists ... carried out with yeast and cell cultures of higher organisms, ...
... addition to being among his most vibrant and celebrated works, ... mutation whose genetic basis has, until now, been a bit ... (March 29) in the journal PLoS Genetics , however, ... behind the distinctive, thick bands of yellow "double flowers" that ...
Cached Biology News:New clinical trial explores novel noninvasive colon cancer screening test 2New clinical trial explores novel noninvasive colon cancer screening test 3Otto Warburg Medal for Alexander Varshavsky 2Otto Warburg Medal for Alexander Varshavsky 3UGA scientists reveal genetic mutation depicted in van Gogh's sunflower paintings 2
... 19 x 29 cm, 1. One ... staining of Coomassie Blue or silver-stain gels ... blots for high sensitivity ECL detection and ... volume, and processing time.Proven design for consistent, ...
Complement C1r [Human]...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... oligos for SYBR Green, TaqMan, LNA spiked ... assays. Highly specific primers are designed by ... BLAST search results. Primer efficiency is enhanced ... connecting to the Mfold server. Beacon Designer ...
Biology Products: